ArticleNPJ biofilms and microbiomes2025
Harnessing dual-channel probiotics to synergistically correct intestinal and vaginal dysbiosis after antibiotic disruption.
Article in NPJ biofilms and microbiomes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Dietary and nutritional strategies for reducing disease risk associated with antibiotic-induced dysbiosis.Gut microbes · 2026Review
- The cervicovaginal gut microbiota axis as a key determinant of systemic physiology.Gut microbes · 2026Review
- Polyendocrine Metabolic Ovarian Syndrome (PMOS; Formerly Polycystic Ovary Syndrome/PCOS) and Susceptibility to Microbial Infections: Mechanisms, Clinical Management, and Reproductive Consequences - A Comprehensive Review.Reproductive sciences (Thousand Oaks, Calif.) · 2026Review
- Chitosan-Based Composite Film Containing Cell-Free Supernatant ofGels (Basel, Switzerland) · 2026Article
- Targeting PPARγ-NF-κB: (+)-catechin reversesFuture microbiology · 2026Article
- Enterococcus hirae Y-HS Alleviates Ulcerative Colitis by Activating PXR/Nrf2-mediated Metabolic-immune Crosstalk.Probiotics and antimicrobial proteins · 2026Article
- Vaginal-Derived Potential Probiotics and Their Postbiotics Alleviate Aerobic Vaginitis via Suppressing TLR4/MyD88/NF-κB Signalling Pathway and Potentially Enhancing Vaginal Barrier.Microbial biotechnology · 2026Article
- Vaginal Microecological Imbalance, Human Papillomavirus Infection, and Cervical Carcinogenesis: Mechanisms and Clinical Implications.International journal of general medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Antibiotics are widely used to treat infectious diseases, yet antibiotic therapy has been shown to disrupt symbiotic microbiota. Notably, the dosage and duration of antibiotic use for specific infections may exert detrimental effects on microbiota in non-infected sites. Here, we propose a dual-channel probiotic delivery strategy to address gut and vaginal dysbiosis caused by antibiotic therapies. In a Helicobacter pylori infection model, oral administration of Limosilactobacillus reuteri NCU-15 alleviated gastritis and protected the intestinal barrier and microbiota. In a vaginal dysbiosis model, intravaginal delivery of Lactobacillus crispatus NCU-23 reduced local inflammation and apoptosis, restoring vaginal microbial homeostasis. In the entero-vaginal disordered mice, dual-channel probiotic therapy produced synergistic effects by reducing inflammation, inhibiting apoptosis, and reestablishing microbial balance. These findings demonstrate the potential of dual-channel probiotic intervention to modulate gut-vaginal microbiota interactions and offer a scientific basis for developing strategies to prevent or treat antibiotic-induced dysbiosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.